High Growth Tech Stocks To Watch For Potential Portfolio Strength
| ALNY Stock | USD 454.38 13.17 2.82% |
Slightly above 62% of Alnylam Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Alnylam Pharmaceuticals suggests that many traders are alarmed. Alnylam Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Alnylam Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
In a week marked by cautious earnings reports and mixed economic signals, global markets saw major indices like the Nasdaq Composite and SP MidCap 400 briefly hit record highs before retreating, while small-cap stocks showed resilience compared to their larger counterparts. As investors navigate this landscape of fluctuating market sentiment and economic uncertainty, identifying high growth tech stocks with strong fundamentals and potential for innovation can be crucial for strengthening...
Read at finance.yahoo.com
 |
Alnylam Pharmaceuticals Fundamental Analysis
We analyze Alnylam Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Alnylam Pharmaceuticals is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Alnylam Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alnylam Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Alnylam Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Alnylam Pharmaceuticals Related Equities
| ARWR | Arrowhead Pharmaceuticals | 2.80 | ||||
| AGIO | Agios Pharm | 1.57 | ||||
| APLS | Apellis Pharmaceuticals | 1.27 | ||||
| BMRN | Biomarin Pharmaceutical | 0.88 | ||||
| SRPT | Sarepta Therapeutics | 0.80 | ||||
| IONS | Ionis Pharmaceuticals | 1.27 | ||||
| INCY | Incyte | 1.72 |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.